SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten...
from PR Newswire: https://ift.tt/2Dg75dk
No comments:
Post a Comment